Skip to content
‹ Back to IndustriesSciences

The Impact of the Russian ASAT Tests

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby  sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test. The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Chris Blackerby · · AsatBanDebrisRussia
Share

Key takeaways

01

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby  sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test.

02

The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

In this bonus episode of Space to Grow, hosts Charity Weeden and Chris Blackerby sit down to discuss kinetic ASAT tests in space and possible silver-linings that came from the most recent test.

The November 2021 Russian ASAT (Anti-Satellite) test shed unprecedented light onto the space community and is estimated to have produced almost 1700 pieces of debris in the 600km range, close to Earth, which was spread throughout other orbital regimes.

Not only did this test launch international attention on debris in space, but it reaffirmed uncertainty in operating in space for many private and public space entities. Space debris, or space “junk” as it is commonly referred to, can range from outdated satellites, to tiny fragments of broken up objects, similar to what the Russian ASAT test created.

The junk clogs up orbital pathways and can cause unforeseen structural damage to orbiting or launching objects. As such, many companies, including Astroscale have condemned ASAT tests in the industry as irresponsible behavior.

While space debris continues to orbit, Blackerby highlighted some silver-linings on the situation, “It’s awareness…when do we see the non-space media and community get in…We had recognition by politicians around the world that this was bad.”

Though not catastrophic in the near-term, the test created so much debris that the resulting awareness in the international community can be viewed as a positive aspect, but not one that the space industry wants to repeat as a normative action.

On ASAT tests, Weeden was firm that we can not allow this activity to, “live in the space environment.” Space actors can not continue doing these tests and apologizing as if they do not have any future, long-term consequences.

“I’m hopeful this will galvanize some sort of ASAT ban,” said Weeden. Given the international attention, the need to get rid of space trash is front and center and a ban on ASAT tests will help keep space accessible to all.

More in This Series

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

CB
Chris Blackerby
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel and Warwick have developed a version of two-dimensional mass spectrometry called Q-2DMS. Until now, only the best-funded centers could afford 2DMS hardware, and Verdel's chief executive argues that the field lacked access, not an understanding of what the method can do. If 2DMS moves onto more common hardware, more labs could evaluate it. Published results show up to tenfold more usable spectral information on closely related or near-isobaric compounds, the look-alike molecules that separation and filtering tend to blur together or drop.

  • 01The reported gain of up to tenfold more usable spectral information applies to closely related or near-isobaric compounds, so the best trial samples are the mixtures chromatography struggles to separate.
  • 02A full time-stamped acquisition can be re-queried after the original sample has degraded or run out, so archived runs could answer questions nobody had thought to ask when the sample was measured.

Oct 9, 2026

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

CB
Chris Blackerby

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512